CytoDyn Inc. (OTCMKTS:CYDY) Sees Large Decline in Short Interest

CytoDyn Inc. (OTCMKTS:CYDY - Get Free Report) was the target of a large decline in short interest in February. As of February 15th, there was short interest totalling 4,724,300 shares, a decline of 25.2% from the January 31st total of 6,311,900 shares. Based on an average daily trading volume, of 5,725,000 shares, the short-interest ratio is presently 0.8 days.

CytoDyn Stock Performance

CytoDyn stock traded down $0.05 during mid-day trading on Friday, reaching $0.20. The company's stock had a trading volume of 8,236,298 shares, compared to its average volume of 2,993,649. CytoDyn has a 12-month low of $0.15 and a 12-month high of $0.48. The company has a market capitalization of $200.36 million, a P/E ratio of -3.38 and a beta of 0.21. The firm's fifty day moving average price is $0.18 and its two-hundred day moving average price is $0.19.

CytoDyn (OTCMKTS:CYDY - Get Free Report) last announced its quarterly earnings results on Tuesday, January 16th. The biotechnology company reported ($0.01) EPS for the quarter.

About CytoDyn

CytoDyn Inc, a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.